956075-49-3

Basic information

• Product Name: N,N-dimethyl-4-Piperidinesulfonamide
• Synonyms: N,N-dimethyl-4-Piperidinesulfonamide;N,N-Dimethylpiperidine-4-sulfonamide
• CAS NO: 956075-49-3
• Molecular Formula: C₇H₁₆N₂O₂S
• Molecular Weight: 192.27914
• Mol File: 956075-49-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N,N-dimethyl-4-Piperidinesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-dimethyl-4-Piperidinesulfonamide(956075-49-3)
• EPA Substance Registry System: N,N-dimethyl-4-Piperidinesulfonamide(956075-49-3)

Safety Data

• Hazardous Substances Data: 956075-49-3(Hazardous Substances Data)

Upstream product

• 287953-54-2 4-(chlorosulfonyl)piperidine-1-carboxylic acid benzyl ester 
• 1083326-06-0 benzyl 4-[(dimethylamino)sulfonyl]-1-piperidinecarboxylate 

Relevant articles and documents

NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST

The present invention relates to a novel pyrrolidine compound having melanocortin receptor agonist activity or a pharmaceutically acceptable salt thereof, and to pharmaceutical applications thereof. The present invention relates to a pyrrolidine derivative represented by formula [I], wherein ring A represents an optionally substituted aryl group or the like; R1 represents an optionally substituted alkyl group or the like; R2 represents a halogen atom or the like; and R3 is an alkyl group substituted with an optionally substituted aryl group or the like, and R4 is a hydrogen atom or the like; or R3 and R4 are terminally attached to each other, and together with the nitrogen atom to which they are attached, form an optionally substituted nitrogen-containing aliphatic heterocyclic ring that may partially contain a double bond; or to a pharmaceutically acceptable salt thereof.

QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoxaline derivatives.